Current status of autologous hematopoietic stem cell transplantation in myeloma

Bone Marrow Transplantation
J Mehta, S Singhal

Abstract

High-dose melphalan with autologous hematopoietic SCT (HSCT) improves response rates and survival in myeloma. This is despite the fact that unlike other hematologic malignancies treated with high-dose therapy and autotransplantation, autografted myeloma patients continue to relapse several years after transplantation and the procedure is not curative in the majority of patients. However, patients surviving for several years with essentially normal quality of life may be considered to be 'operationally cured.' Also, unlike with other hematologic malignancies relapsing after an autograft, recurrent disease can be treated with novel agents or repeat high-dose chemotherapy and autologous or allogeneic HSCT--and long-term survival is seen in a number of patients after relapse. Although tandem transplantation is clearly superior to a single autograft, it is unclear if this should be offered to all patients routinely or only to those not attaining CR after one transplant. It is also unclear if novel agents should be used before transplantation or reserved for relapse. Despite their excellent activity, there is no evidence that novel agents such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and HSCT, an...Continue Reading

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G TricotB Barlogie
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Sep 13, 2003·BMJ : British Medical Journal·Seema Singhal
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van AgthovenP Sonneveld
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
May 17, 2005·Bone Marrow Transplantation·B SirohiJ Treleaven
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Paul FermandUNKNOWN Group Myelome-Autogreffe
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Jan 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart BarlogieJohn C Crowley
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Mar 17, 2006·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Attila TárnokFrank Emmrich
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Aug 31, 2006·British Journal of Haematology·Bart BarlogieJohn Crowley
May 9, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoMichele Baccarani
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Seema Singhal, Jayesh Mehta
Aug 24, 2007·Current Treatment Options in Oncology·Seema Singhal, Jayesh Mehta

❮ Previous
Next ❯

Citations

Aug 21, 2009·Annals of Hematology·Adrian TempesculChristian Berthou
Apr 8, 2009·Bone Marrow Transplantation·A López-OteroG J Ruiz-Argüelles
Jun 10, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Shashideep SinghalPremashis Kar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.